SCHEMBL4930459

SCHEMBL4930459

O=c1[nH]c2ccc(Cl)cc2n1-c1ccc(OC(F)(F)F)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.49
MEN1 O00255 1/20 0.49
LMNA P02545 1/20 0.49
KMT2A Q03164 1/20 0.49
POLB P06746 1/20 0.47
DAO P14920 1/20 0.47
AURKA O14965 1/20 0.45
DDR1 Q08345 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.42
MAT2A P31153 2/20 0.41
PGR P06401 1/20 0.40
ACLY P53396 1/20 0.40
GABRP O00591 1/20 0.40
GABRD O14764 1/20 0.40
GABRA1 P14867 1/20 0.40
GABRB1 P18505 1/20 0.40
GABRG2 P18507 1/20 0.40
GABRB3 P28472 1/20 0.40
GABRA5 P31644 1/20 0.40
GABRA3 P34903 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4930971 0.89 L3MBTL1 (0.46) L3MBTL1MEN1LMNAKMT2APOLB
SCHEMBL4922308 0.86 L3MBTL1 (0.48) L3MBTL1MEN1LMNAKMT2APOLB
SCHEMBL4929848 0.85 PSMB8 (0.47) L3MBTL1MEN1KMT2APOLBDDR1
SCHEMBL4933359 0.84 MEN1 (0.46) L3MBTL1MEN1LMNAKMT2ADAO
SCHEMBL11348908 0.83 LMNA (0.62) L3MBTL1MEN1LMNAKMT2APOLB
SCHEMBL4931135 0.83 GABRP (0.56) L3MBTL1MEN1LMNAKMT2ADAO
SCHEMBL4933166 0.80 MEN1 (0.49) L3MBTL1MEN1LMNAKMT2ADAO
SCHEMBL8886284 0.78 MEN1 (0.77) L3MBTL1MEN1LMNAKMT2ADAO
SCHEMBL31743953 0.78 MEN1 (0.77) L3MBTL1MEN1LMNAKMT2ADAO
SCHEMBL4928761 0.78 L3MBTL1 (0.47) L3MBTL1MEN1LMNAKMT2ADAO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080021069-A1 Receptor Function Regulating Agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-24 US disclosed
US-20080021069-A1 Receptor Function Regulating Agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-24 US disclosed
US-20080021069-A1 Receptor Function Regulating Agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-24 US disclosed
EP-1810677-A1 RECEPTOR FUNCTION REGULATING AGENT Takeda Pharmaceutical Company Limited (JP) 2007-07-25 EP disclosed
EP-1810677-A1 RECEPTOR FUNCTION REGULATING AGENT Takeda Pharmaceutical Company Limited (JP) 2007-07-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080021069-A1 Receptor Function Regulating Agent GPR119, INSR, GPR65 L3MBTL1 4264/4885MEN1 4097/4885LMNA 4744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.